A Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma

About this Study

The primary purpose of this study is to determine the event free survival and overall survival of children with completely resected ependymoma treated with post-operative conformal radiation therapy and then randomized to receive or not to receive four cycles of post radiation maintenance chemotherapy with vincristine, cisplatin, cyclophosphamide, and etoposide (VCEC).  The secondary purpose of the study is to determine the event free survival and overall survival of children with incompletely resected ependymoma who are unable to achieve a complete response by a) post-operative chemotherapy or by b) second surgery who will then be non-randomly assigned to conformal radiation therapy followed by four cycles of maintenance chemotherapy (VCEC). 

Sponsor Protocol ID:ACNS0831
IRB Number:2010-0098
Actively Enrolling
Interventional
Phase 3
May 28, 2019
Eligibility Criteria
1 year old
21 years old
Both Male and Female
Yes
Yes
No

Inclusion CriteriaPatients must be greater than 12 months of age and less than 21 years of age at the time of study enrollment.

Exclusion Criteria
  • Patients with evidence of metastatic disease will be excluded. 
  •  Patients with a diagnosis of spinal cord ependymoma, myxopapillary ependymoma, subependymoma, ependymoblastoma, or mixed glioma are NOT eligible.  
  • Pregnant female patients are not eligible for this study.  
  • Males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. 
  • Lactating females may not participate unless they have agreed not to breastfeed a child while on this study.

Categories Click category to view its trials.
Cancer
Pediatrics
Participating Locations
Children’s of Mississippi Hospital - Blair E. Batson Tower
Children's of Mississippi Center for Cancer and Blood Disorders
Contact Information
Contact Name: Leslie Johnson
Phone Number: 601-815-3067
Email: lnjohnson@umc.edu
Principal Investigator:Benjamin Stronach
How to participate in our Clinical Trials